Table 1. Receipt of Aflibercept During 2 Years of Follow-up by Baseline Characteristics.

Characteristic	No.	Received Aflibercept, No.	Cumulative Probability, % (95% CI)	Hazard Ratio (95% CI)	P Value
Sex
Male	149	48	34 (27-43)	0.86 (0.55-1.34)	.50
Female	87	32	39 (29-50)
Age, y
≥60	122	32	28 (21-37)	0.56 (0.36-0.88)	.01a
<60	114	48	44 (35-54)
Race/ethnicity
Nonwhite	73	23	33 (23-45)	0.88 (0.54-1.43)	.60
Non-Hispanic white	161	56	37 (30-45)
HbA1c value, %
≥7.5	120	41	37 (29-47)	1.18 (0.75-1.86)	.47b
<7.5	106	34	32 (24-42)
Visual acuity, Snellen equivalent (letter score)
20/25 (83-79)	85	35	42 (32-53)	1.42 (0.91-2.21)	.12c
20/20 or better (≥84)	151	45	32 (25-40)
OCT central subfield thickness (Zeiss-Stratus equivalent), μm
≥300	115	51	45 (37-55)	1.98 (1.26-3.13)	.003d
<300	121	29	26 (19-35)
Diabetic retinopathy severity graded on color fundus photographs (ETDRS retinopathy severity level)14
≥47 (Moderately severe NPDR and above)	80	38	51 (40-63)	2.22 (1.42-3.47)	<.001e
≤43 (Moderate NPDR and below)	149	39	27 (21-36)
Prior treatment for DME in the study eye
Yes	34	13	41 (26-60)	1.22 (0.67-2.21)	.51
No	202	67	35 (29-42)
Recent or planned (within 4 mo) diabetic macular edema treatment in the nonstudy eye
Yes	92	47	52 (42-62)	2.55 (1.64-3.99)	<.001
No	144	33	25 (18-33)

Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy Study; HbA_1c, glycated hemoglobin; NPDR, nonproliferative diabetic retinopathy; OCT, optical coherence tomography.

^aContinuous age: HR for 10-year increase, 0.85 (95% CI, 0.70-1.04), P = .11.

^bContinuous HbA_1c: HR for 1%-increase, 1.10 (95% CI, 0.96-1.26), P = .18.

^cContinuous visual acuity: HR for 5-letter decrease, 1.16 (95% CI, 0.85-1.59), P = .34.

^dContinuous OCT central subfield thickness: HR for 25-μm increase, 1.10 (95% CI, 1.03-1.18), P = .005.

^eOrdinal diabetic retinopathy severity level: HR for 1-step increase, 1.30 (95% CI, 1.14-1.49). P < .001.